Press Releases

BIA launches biotech manifesto

The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has today launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.

BIA responds to the Smith - Reid Review on international research partnerships

Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) said: “Thanks to new advances in science and innovation, we are at the cusp of a new industrial revolution, however Brexit is causing much uncertainty for UK SMEs. I welcome the publication of this important review and it is good to see the Science Minister recognising the valuable contribution the life sciences sector makes in discovering new cures for life-threatening diseases.

BIA announces new Chair and appointments to the BIA Board

Following the BIA AGM at the UK Bioscience Forum, the Association has announced the new Chair and members who have been elected to its Board of Directors.

BIA welcomes news of deal between Vertex and NHS England

Steve Bates OBE, CEO of the BIA said: “We welcome today’s announcement that NHS England and Vertex have been able to reach a deal and that this drug will soon be available to patients and their families. This is one of a number of deals that the NHS has reached with industry to bring life-saving treatments to patients, showing that the UK’s health service is committed to innovation and being at the cutting edge of medical products.

 

Member News

PhoreMost and Sentinel Oncology expand collaboration to jointly accelerate novel glioma therapeutic through preclinical development

Lead allosteric PLK1 inhibitor to progress through preclinical and IND enabling studies

Cognate BioServices announces acquisition of Cobra Biologics

- Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products - EW Healthcare Partners and its co-investors provide the financing for the transaction

Repositive unveils molecular search functionality for its Cancer Models Platform at ELRIG Drug Discovery

Repositive is unveiling molecular search functionality for its Cancer Models Platform today at ELRIG Drug Discovery. The first version of this innovative feature enables pharma and biotech scientists to search Repositive’s cancer model directory by their gene of interest and explore different mutations available to ensure they source a cancer model with the right molecular profile for their preclinical study.

New report indicates more than 10% of the UK’s top female BioBusiness talent is based at Stevenage Bioscience Catalyst

A new report released today by BioBeat entitled “50 Movers & Shakers in BioBusiness 2019” includes five women from organisations based at Stevenage Bioscience Catalyst (SBC) as well as two Board members. The report highlights the top female talent in the pharma and biotech sectors within the UK.

 

BIA blog

CEO Update|Monday 11 November 2019

Great news for NHS patients this morning as two cannabis-based medicines - Epidyolex and Sativex, developed by BIA member GW Pharmaceuticals, have been approved for use by the NHS in England.

Is biotech bad news?

Is biotech bad news? That was the question asked of an expert panel of media and communications experts at the recent UK Bioscience Forum.

What does the General Election mean for BIA members?

“You’re joking!” as Brenda from Bristol might say. “Not ANOTHER one!” But here we are, only nine years since the Fixed Term Parliaments Act (FTPA) supposedly kept General Elections five years apart, heading to the polls for the third time in four years.

CEO Update|Monday 04 November 2019

The UK will have a General Election on December 12 and the “do or die” 31 October Brexit deadline has come and gone.

 

Our publications

Please find a selection of featured BIA publications below. To see our full publications library, click here

Influencing and shaping our sector, BIA update: January - April 2018

This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.

Biotech Financing Update: December 2017 to February 2018

The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.

Pipeline Progressing: The UK's Global Bioscience Cluster in 2017

A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.

BIA Best practice guide for communicating R&D

Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.